Praxis Precision Medicines, Inc. (PRAX) — SEC Filings
Praxis Precision Medicines, Inc. (PRAX) — 50 SEC filings. Latest: 10-Q (May 7, 2026). Includes 17 8-K, 16 SC 13G/A, 7 SC 13G.
View Praxis Precision Medicines, Inc. on SEC EDGAR
Overview
Praxis Precision Medicines, Inc. (PRAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 14, 2026: On April 14, 2026, Praxis Precision Medicines, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business updates beyond its routine reporting nature.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 47 neutral. The dominant filing sentiment for Praxis Precision Medicines, Inc. is neutral.
Filing Type Overview
Praxis Precision Medicines, Inc. (PRAX) has filed 6 10-Q, 17 8-K, 1 DEFA14A, 2 10-K, 16 SC 13G/A, 7 SC 13G, 1 DEF 14A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PRAX's 25 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
Key Executives
- Dr. Jeffrey S. Farber
- Dr. Steven M. Paul
- Stephen A. Schwarzman
Industry Context
The pharmaceutical preparations industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Praxis Precision Medicines focus on developing novel therapies, often in specialized therapeutic areas, facing intense competition from both established players and emerging biotechs.
Top Tags
8-K (8) · disclosure (4) · SEC Filing (4) · 10-Q (4) · sec-filing (3) · biotech (3) · Praxis Precision Medicines (3) · institutional-ownership (3) · regulatory-filing (2) · filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating no commercial products |
| Period End Date | 2025-06-30 | the end of the reporting period for this 10-Q |
| Filing Date | 2025-08-04 | when the 10-Q was filed with the SEC |
| Reporting Period | 2025 Q1 | Indicates the first quarter of fiscal year 2025. |
| Fiscal Year End | 2024 | The period covered by the 10-K filing. |
| Reporting Period End Date | 2024-09-30 | Indicates the end of the fiscal quarter covered by the report. |
| First Half 2024 | 2024-01-01 to 2024-06-30 | Financials for the first six months of 2024 are detailed. |
| First Half 2023 | 2023-01-01 to 2023-06-30 | Comparative financial data from the previous year's first half. |
| Conformed Period of Report | 2024-03-31 | Quarterly period ending date |
| Filed As Of Date | 2024-05-13 | Date of filing |
| Quarter Start Date | 2024-01-01 | Beginning of the reporting quarter |
| Prior Year Quarter End | 2023-03-31 | End of the comparable quarter in the previous year |
| Period of Report | 20240605 | Conformed period of report |
| Initiation of Essential3 | Q4 2023 | Phase 3 program for ulixacaltamide |
| Positive Phase 2a Results | Q1 2024 | For PRAX-628 in epilepsy patients |
Forward-Looking Statements
- {"claim":"Blackstone and its affiliates will maintain a passive investment strategy in Praxis Precision Medicines, Inc.","entity":"Blackstone Holdings I/II GP L.L.C.","targetDate":"Next 12 months","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Praxis Precision Medicines, Inc. (PRAX)?
Praxis Precision Medicines, Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 17 8-K, 16 SC 13G/A, 7 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRAX filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Praxis Precision Medicines, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Praxis Precision Medicines, Inc. (PRAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Praxis Precision Medicines, Inc.?
Key financial highlights from Praxis Precision Medicines, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PRAX?
The investment thesis for PRAX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Praxis Precision Medicines, Inc.?
Key executives identified across Praxis Precision Medicines, Inc.'s filings include Dr. Jeffrey S. Farber, Dr. Steven M. Paul, Stephen A. Schwarzman.
What are the main risk factors for Praxis Precision Medicines, Inc. stock?
Of PRAX's 25 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Praxis Precision Medicines, Inc.?
Recent forward-looking statements from Praxis Precision Medicines, Inc. include guidance on {"claim":"Blackstone and its affiliates will maintain a passive investment strategy in Praxis Precision Medicines, Inc.".